Analyst Ratings for Valeant Pharmaceuticals (VRX)
VRX Rating Summary
VRX Price Target Summary
- Highest: $80.00 (Deutsche Bank)
- Lowest: $48.00 (Wells Fargo)
- Average: $62.83
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$62.83 (-17.4%)
Avg. $ Target:
$62.83 (-17.4%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/27/2013 | Ameriprise Financial | New Coverage | Buy (N/A) |
N/A (N/A) |
74.40 | 76.04 | 2.2% | Details |
| 9/14/2012 | Morgan Stanley | Downgrade | Equalweight (Overweight) |
N/A (N/A) |
58.64 | 76.04 | 29.67% | Details |
| 7/13/2012 | Goldman Sachs | New Coverage | Neutral (N/A) |
48.00 (N/A) |
45.03 | 76.04 | 68.87% | Details |
| 5/3/2012 | CRT Capital | Downgrade | Fairly Valued (N/A) |
N/A (N/A) |
50.49 | 76.04 | 50.6% | Details |
| 1/26/2012 | Piper Jaffray | Downgrade | Neutral (N/A) |
54.00 (N/A) |
50.72 | 76.04 | 49.92% | Details |
| 3/31/2011 | TD Securities | Upgrade | Buy (N/A) |
N/A (N/A) |
50.08 | 76.04 | 51.84% | Details |
| 2/14/2011 | Collins Stewart » Updated 5/2/2011 |
New Coverage | Buy (N/A) |
N/A (N/A) |
40.54 | 76.04 | 87.57% | Details |
| 1/7/2011 | Lazard Capital | Upgrade | Buy (N/A) |
N/A (N/A) |
35.55 | 76.04 | 113.9% | Details |
| 11/8/2010 | Ladenburg Thalmann | New Coverage | Buy (N/A) |
N/A (N/A) |
27.15 | 76.04 | 180.07% | Details |
| 10/11/2010 | Wells Fargo » Updated 12/22/2011 |
Upgrade | Market Perform (N/A) |
48.00 (N/A) |
26.84 | 76.04 | 183.31% | Details |
| 10/4/2010 | Deutsche Bank » Updated 4/4/2013 |
New Coverage | Buy (N/A) |
80.00 (N/A) |
25.75 | 76.04 | 195.3% | Details |
